Research from Redeye, Redeye AB

Redeye

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen). 

Expertise in Denmark, Finland, Norway and Sweden.

Research from Redeye

Redeye AB

Specialists in innovative and fast-growing Nordic companies within Life Science and Technology.

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen).

Equity Bottom-Up

<ul><li>Redeye comments on OncoZenge’s announcement that the first patient has been enrolled in the pivotal Phase III BEAM-Pain trial of BupiZenge.</li><li>We view this as a major operational milestone, marking the company's successful transition from regulatory preparation to clinical execution and bringing BupiZenge another important step closer to potential market approval in Europe.</li></ul>

Redeye comments on OncoZenge’s announcement that the first patient has been enrolled in the pivotal Phase III BEAM-Pain trial of BupiZenge.We view this as a major operational milestone, marking the company's successful transition from regulatory preparation to clinical execution and bringing BupiZenge another important step closer to potential market approval in Europe.

OncoZenge: First patient enrolled in Pivotal Phase III Study

Oncozenge

OncoZenge: First patient enrolled in Pivotal Phase III Study